Cargando…

Easy‐to‐use algorithm would provide faster diagnoses for mucopolysaccharidosis type I and enable patients to receive earlier treatment

AIM: The aim of this study was to develop an algorithm to prompt early clinical suspicion of mucopolysaccharidosis type I (MPS I). METHODS: An international working group was established in 2016 that comprised 11 experts in paediatrics, rare diseases and inherited metabolic diseases. They reviewed r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tylki‐Szymańska, Anna, De Meirleir, Linda, Di Rocco, Maja, Fathalla, Waseem M., Guffon, Nathalie, Lampe, Christina, Lund, Allan M., Parini, Rossella, Wijburg, Frits A., Zeman, Jiri, Scarpa, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Regular Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055821/ https://www.ncbi.nlm.nih.gov/pubmed/29797470 http://dx.doi.org/10.1111/apa.14417

Ejemplares similares

International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome
por: Parini, Rossella, et al.
Publicado: (2018)

Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder
por: Wijburg, Frits A, et al.
Publicado: (2013)

Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease
por: Scarpa, Maurizio, et al.
Publicado: (2011)

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
por: Wraith, J. Edmond, et al.
Publicado: (2007)

Open issues in Mucopolysaccharidosis type I-Hurler
por: Parini, Rossella, et al.
Publicado: (2017)

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2017)

Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
por: Magner, Martin, et al.
Publicado: (2022)

Treatment of thoracolumbar kyphosis in patients with mucopolysaccharidosis type I: results of an international consensus procedure
por: Kuiper, Gé-Ann, et al.
Publicado: (2019)

Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland
por: Żuber, Zbigniew, et al.
Publicado: (2023)

Nobody said it would be easy.
por: Goehl, T J
Publicado: (1995)

Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome)
por: Valstar, Marlies J, et al.
Publicado: (2011)

Genotype‐phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry
por: Clarke, Lorne A., et al.
Publicado: (2019)

The Effect of Recombinant Human Iduronate-2-Sulfatase (Idursulfase) on Growth in Young Patients with Mucopolysaccharidosis Type II
por: Żuber, Zbigniew, et al.
Publicado: (2014)

Human pulmonary artery endothelial cells in the model of mucopolysaccharidosis VI present a prohypertensive phenotype
por: Golda, Adam, et al.
Publicado: (2015)

Prediction of phenotypic severity in mucopolysaccharidosis type IIIA
por: Knottnerus, Suzan J. G., et al.
Publicado: (2017)

Attenuated osteoarticular phenotype of type VI mucopolysaccharidosis: a report of four patients and a review of the literature
por: Jurecka, Agnieszka, et al.
Publicado: (2013)

A rare late progression form of Sly syndrome mucopolysaccharidosis
por: Guffon, Nathalie, et al.
Publicado: (2019)

Attitudes of relatives of mucopolysaccharidosis type III patients toward preconception expanded carrier screening
por: Nijmeijer, Stephanie C. M., et al.
Publicado: (2020)

Macular Changes in a Mucopolysaccharidosis Type I Patient with Earlier Systemic Therapies
por: Magalhães, Augusto, et al.
Publicado: (2021)

Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype
por: Valstar, Marlies J., et al.
Publicado: (2010)

Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications
por: Kuiper, Gé-Ann, et al.
Publicado: (2018)

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
por: D’Aco, Kristin, et al.
Publicado: (2012)

Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure
por: de Ru, Minke H, et al.
Publicado: (2011)

Preconception expanded carrier screening: a focus group study with relatives of mucopolysaccharidosis type III patients and the general population
por: Conijn, Thirsa, et al.
Publicado: (2021)

The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers
por: Tylki-Szymańska, Anna, et al.
Publicado: (2022)

Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure
por: Langereis, Eveline J, et al.
Publicado: (2013)

Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI
por: Harmatz, Paul R., et al.
Publicado: (2013)

Atypical microbial infections of digestive tract may contribute to diarrhea in mucopolysaccharidosis patients: a MPS I case study
por: Węgrzyn, Grzegorz, et al.
Publicado: (2005)

An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life
por: Kingma, Sandra DK, et al.
Publicado: (2013)

Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Ficicioglu, Can, et al.
Publicado: (2017)

RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Earlier time to aerobic exercise is associated with faster recovery following acute sport concussion
por: Lawrence, David Wyndham, et al.
Publicado: (2018)

Transforming cancer outcomes in England: earlier and faster diagnoses, pathways to success, and empowering alliances
por: Harrison, Christopher J, et al.
Publicado: (2019)

Diabetes: Concepts of β-Cell Organ Dysfunction and Failure Would Lead to Earlier Diagnoses and Prevention
por: Charles, M. Arthur, et al.
Publicado: (2021)

“Growth patterns in children with mucopolysaccharidosis type I-Hurler after hematopoietic stem cell transplantation: Comparison with untreated patients”
por: Cattoni, Alessandro, et al.
Publicado: (2021)

Easy, Faster, and Not Bloody: Providers' Perceptions on PrePex™ in South Africa
por: Milovanovic, Minja, et al.
Publicado: (2016)

Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
por: Bugiani, Marianna, et al.
Publicado: (2023)

The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosis
por: Hennermann, Julia B., et al.
Publicado: (2020)

Pregnancy in patients with mucopolysaccharidosis: a case series
por: Stewart, Fiona J., et al.
Publicado: (2016)

Growth impairment and limited range of joint motion in children should raise suspicion of an attenuated form of mucopolysaccharidosis: expert opinion
por: Guffon, Nathalie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h60o0tlb891braikf98845hsag